Ab Science’s Phase 3 ALS Trial: A Key Development for Investors

Ab Science ((ABSCF)) announced an update on their ongoing clinical study.

Ab Science is spearheading a pivotal Phase 3 clinical trial titled ‘A Prospective, Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Groups, Phase 3 Trial to Compare the Efficacy and Safety of Masitinib in Combination With Standard of Care Versus Placebo in Combination With Standard of Care in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)’. The study aims to evaluate the efficacy and safety of masitinib, an investigational drug, in combination with riluzole, compared to a placebo with riluzole, for treating ALS, a debilitating neurodegenerative disease.

The trial tests masitinib, an experimental drug administered orally at a dose of 3.0 mg/kg/day, with potential escalation to 4.5 mg/kg/day, alongside riluzole, a standard ALS treatment. The placebo group receives a matched placebo with riluzole, ensuring a rigorous comparison.

This interventional study employs a randomized, parallel design with quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are blinded to the treatment allocations. The primary goal is to assess treatment efficacy and safety.

The study is set to commence on September 11, 2025, with the primary completion date yet to be announced. The latest update was submitted on October 2, 2025. These dates are crucial for tracking the study’s progress and anticipated milestones.

For investors, this update could influence AB Science’s stock performance, as successful trial outcomes may enhance market confidence and competitive positioning in the ALS treatment landscape. The trial’s progress is a key indicator for stakeholders monitoring developments in neurodegenerative disease therapies.

The study is ongoing, with further details available on the ClinicalTrials portal.